Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymopentin Immune Modulation in Sepsis
ChiCTR2200060069Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of thymopentin in sepsis (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 28-day mortality rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
thymopentin
03
Conditions
sepsis
Beyond the preview
Go deeper on ChiCTR2200060069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060069.